fenofibrate has been researched along with Angiogenesis, Pathologic in 7 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fenofibrate was tested in vivo, in 30 coronary arteries of 10 pigs (1g/day, orally) and was compared to placebo." | 5.33 | Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. ( Aihara, K; Daida, H; Kasai, T; Miyauchi, K; Yokoyama, T, 2006) |
| "Fenofibrate -a peroxisome proliferator-activated receptor-a agonist- is an angiostatic agent that is commonly used in human liver diseases, therefore it may interfere with the angiogenetic process required for endometriosis." | 3.75 | Fenofibrate causes regression of endometriotic implants: a rat model. ( Bayraktar, N; Onalan, G; Zeyneloglu, HB, 2009) |
| "Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors." | 2.79 | A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014) |
| "Furthermore, fenofibrate suppressed scar formation by reducing type III collagen expression." | 1.46 | Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn. ( Arima, T; Kang, D; Nagasaka, S; Nakano, Y; Shimizu, A; Takahashi, H; Uchiyama, M, 2017) |
| "Fenofibrate was tested in vivo, in 30 coronary arteries of 10 pigs (1g/day, orally) and was compared to placebo." | 1.33 | Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. ( Aihara, K; Daida, H; Kasai, T; Miyauchi, K; Yokoyama, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arima, T | 1 |
| Uchiyama, M | 1 |
| Nakano, Y | 1 |
| Nagasaka, S | 1 |
| Kang, D | 1 |
| Shimizu, A | 1 |
| Takahashi, H | 1 |
| Yuan, J | 1 |
| Tan, JTM | 1 |
| Rajamani, K | 1 |
| Solly, EL | 1 |
| King, EJ | 1 |
| Lecce, L | 1 |
| Simpson, PJL | 1 |
| Lam, YT | 1 |
| Jenkins, AJ | 1 |
| Bursill, CA | 1 |
| Keech, AC | 1 |
| Ng, MKC | 1 |
| Robison, NJ | 1 |
| Campigotto, F | 1 |
| Chi, SN | 1 |
| Manley, PE | 1 |
| Turner, CD | 1 |
| Zimmerman, MA | 1 |
| Chordas, CA | 1 |
| Werger, AM | 1 |
| Allen, JC | 1 |
| Goldman, S | 1 |
| Rubin, JB | 1 |
| Isakoff, MS | 1 |
| Pan, WJ | 1 |
| Khatib, ZA | 1 |
| Comito, MA | 1 |
| Bendel, AE | 1 |
| Pietrantonio, JB | 1 |
| Kondrat, L | 1 |
| Hubbs, SM | 1 |
| Neuberg, DS | 1 |
| Kieran, MW | 1 |
| Farris, RA | 1 |
| Price, ET | 1 |
| Onalan, G | 1 |
| Zeyneloglu, HB | 1 |
| Bayraktar, N | 1 |
| Varet, J | 1 |
| Vincent, L | 1 |
| Mirshahi, P | 1 |
| Pille, JV | 1 |
| Legrand, E | 1 |
| Opolon, P | 1 |
| Mishal, Z | 1 |
| Soria, J | 1 |
| Li, H | 1 |
| Soria, C | 1 |
| Kasai, T | 1 |
| Miyauchi, K | 1 |
| Yokoyama, T | 1 |
| Aihara, K | 1 |
| Daida, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500] | Phase 2 | 101 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.61 |
27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.31 |
Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | .25 |
As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | |
| 5-drug Metronomic Antiangiogenic Regimen | 1 | 12 | 36 | 47 | 1 |
1 trial available for fenofibrate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxi | 2014 |
6 other studies available for fenofibrate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn.
Topics: Alkalies; Angiopoietin-1; Angiopoietin-2; Animals; Burns, Chemical; Cicatrix; Collagen Type III; Cor | 2017 |
Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARĪ±-Independent Modulation of Thioredoxin-Interacting Protein.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Fenofibrate; Glucose; Hindlimb; Ischemia | 2019 |
Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy.
Topics: ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Biomark | 2017 |
Fenofibrate causes regression of endometriotic implants: a rat model.
Topics: Animals; Ascitic Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Endometriosis; End | 2009 |
Fenofibrate inhibits angiogenesis in vitro and in vivo.
Topics: Actins; Apoptosis; Capillaries; Cell Cycle; Cell Line; Cyclooxygenase 2; Dermis; Endothelium; Fenofi | 2003 |
Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models.
Topics: Angioplasty, Balloon, Coronary; Animals; Coronary Restenosis; Coronary Vessels; Fenofibrate; Hyperpl | 2006 |